Although harmful in large quantities, hydrogen sulfide may ameliorate the health consequences of aging when small doses are applied to the mitochondria.
Celgene receives exclusive options to license cell therapies utilizing Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L activity in a multi-year strategic collaboration; Celgene also gains exclusive options to two Kyn therapeutic programs
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.